```
=> d his

     (FILE 'HOME' ENTERED AT 15:29:02 ON 31 AUG 2000)

     FILE 'REGISTRY' ENTERED AT 15:29:08 ON 31 AUG 2000
L1                STRUCTURE UPLOADED
L2              1 S L1 SSS SAM
L3             95 S L1 SSS FUL

     FILE 'CAPLUS' ENTERED AT 15:30:13 ON 31 AUG 2000
L4              2 S L3

     FILE 'CAOLD' ENTERED AT 15:31:34 ON 31 AUG 2000

=> s l3

L5              0 L3
```

=>
Uploading 09336266.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS
L1 STR



G1

G2 N,CH

G3 [@1],[@2]

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 13:35:53 FILE 'MARPAT'
SAMPLE SCREEN SEARCH COMPLETED - 1148 TO ITERATE

87.1% PROCESSED 1000 ITERATIONS 1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.08

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 21089 TO 24831
PROJECTED ANSWERS: 1 TO 86

L2 1 SEA SSS SAM L1

=> d scan l2

L2 1 ANSWERS MARPAT COPYRIGHT 2000 ACS
IC ICM C07D213-84
ICS A01N043-40; A01N047-36; A01N047-18
CC 27-16 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 5
TI Preparation of fungicidal anilinocyanopyridines
ST anilinocyanopyridine prepn agrochem fungicide; cyanopyridine anilino prepn
fungicide; pyridine anilinocyano prepn fungicide
IT Fungicides and Fungistats
(agrochem., anilinocyanopyridines as)
IT 132132-94-6P 132132-95-7P 132132-96-8P 132132-97-9P 132132-98-0P
132132-99-1P 132133-00-7P 132133-01-8P 132133-02-9P 132133-03-0P
132133-04-1P 132133-05-2P 132133-06-3P 132133-07-4P 132133-08-5P
132133-09-6P 132133-10-9P 132133-11-0P 132133-12-1P 132133-13-2P
132133-14-3P 132133-15-4P 132133-16-5P 132133-17-6P 132133-18-7P
132133-19-8P 132133-20-1P 132133-21-2P 133946-48-2P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of, as fungicide)
IT 29091-09-6 30464-06-3
RL: RCT (Reactant)
(reaction of, in prepn. of fungicides)
IT 98-09-9, Benzenesulfonyl chloride
RL: RCT (Reactant)
(sulfonylation by, of anilinocyanopyridine deriv., in prepn. of fungicides)

MSTR 1



G1 = OPh (SO)
G4 = 22



G7 = 34



G9 = NH2

DER: and salts with plant acceptable cations
MPL: claim 1

ALL ANSWERS HAVE BEEN SCANNED

```
=> s l1 sss ful

FULL SEARCH INITIATED 13:36:24 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED -  23310 TO ITERATE

 20.8% PROCESSED    4852 ITERATIONS  (     1 INCOMPLETE)       4 ANSWERS

 43.1% PROCESSED   10049 ITERATIONS  (     2 INCOMPLETE)      10 ANSWERS

 62.6% PROCESSED   14581 ITERATIONS  (     2 INCOMPLETE)      15 ANSWERS

 84.5% PROCESSED   19694 ITERATIONS  (     2 INCOMPLETE)      21 ANSWERS

 94.7% PROCESSED   22085 ITERATIONS  (     2 INCOMPLETE)      23 ANSWERS

 98.8% PROCESSED   23030 ITERATIONS  (     2 INCOMPLETE)      23 ANSWERS

100.0% PROCESSED   23310 ITERATIONS  (     2 INCOMPLETE)      23 ANSWERS
SEARCH TIME: 00.02.00

L3            23 SEA SSS FUL L1

=> d l3 1-23 bib,abs
```

L3 ANSWER 1 OF 23 MARPAT COPYRIGHT 2000 ACS
AN 132:308342 MARPAT
TI Preparation of pyridyl-1,2,4-triazoles as acaricides and insecticides
IN Tisdell, Francis E.; Johnson, Peter L.; Pechacek, James T.; Bis, Scott J.;
Hedge, Vidyadhar B.; Schoonover, Joe R., Jr.; Ripa, Perry V.; Dintenfass, Leonard P.; Gifford, James M.; Thibault, Thomas D.; Ash, Mary L.; Devries,
Donald H.; Martin, Timothy P.
PA Dow Agrosciences Llc, USA
SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000024735	A1	20000504	WO 1999-US24751	19991022

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1998-105356 19981023
GI



I

AB Title compds. [I; 1 of X,Y = H, alkyl, Ph, etc. and the other = (un)substituted Ph, -pyridyl, -thienyl, etc.; Z = (un)substituted pyridyl]
were prepd. Thus, 3,5-dichloro-4-pyridinethioamide was S-methylated and the product N-acylated by 2,4-Cl2C6H3COCl to give ZC(SMe):NCOC6H3Cl2-2,4 (Z = 3,5-dichloro-4-pyridyl) which was cyclocondensed with MeNHNH2 to give
I (X = Me, Y = C6H3Cl2-2,4, Z = 3,5-dichloro-4-pyridyl). Data for biol. activity of I were given.
RE.CNT 11
RE
(1) Baldwin, J; US 3984558 A 1976 CAPLUS
(2) Baldwin, J; US 4011218 A 1977 CAPLUS
(5) Goedecke Ag; DE 2258036 A 1974 CAPLUS
(8) Lepetit Spa; DE 2358011 A 1974 CAPLUS
(9) Novello, F; US 3963731 A 1976 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 23 MARPAT COPYRIGHT 2000 ACS
AN 132:222531 MARPAT
TI Preparation of thiazole derivatives as p38 inhibitors
IN Salituro, Francesco; Bemis, Guy; Cochran, John
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000017175	A1	20000330	WO 1999-US21337	19990916
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9962514	A1	20000410	AU 1999-62514	19990916
PRAI US 1998-100972		19980918		
WO 1999-US21337		19990916		

GI



I



II

AB The present invention provides inhibitors of p38 having general formulas I and II [X = O, S, NR or C(R)2; Y = CR or N; Z = CH or N; M = CO, CHOH, or CH2; n = 0 or 1; Q1 = 5-6 membered arom. carbocyclic or heterocyclic ring system, or an 8-10 membered bicyclic ring system comprising arom. carbocyclic rings, arom. heterocyclic rings or a combination of an arom. carbocyclic ring and an arom. heterocyclic ring, and Q2 = H, CO7R',

CON(R')2, or a (C1-c4) branched or straight-chain alkyl optionally contg. 1-3 substituents independently selected from A, T-C(O)R', OPO3H2, NR'2, N(R'), OR', CO2R', CON(R')2, or SO2N(R2)2; or a 5-6 membered arom. carbocyclic or heterocyclic ring system, or an 8-10 membered bicyclic ring system comprising arom. carbocyclic rings, arom. heterocyclic rings or a combination of an arom. carbocyclic ring and an arom. heterocyclic ring]. No biol. data is given.

RE.CNT 4

RE

(1) Farbwerke Hoechst Aktiengesellschaft; DE 896809 C 1952
(2) Galullo, V; WO 9827098 A 1998
(3) Hanson, G; EXPERT OPINION ON THERAPEUTIC PATENTS 1997, V7(7), P729 CAPLUS
(4) Pfizer Ltd; EP 0424021 A 1991

L3 ANSWER 3 OF 23 MARPAT COPYRIGHT 2000 ACS
AN 131:336949 MARPAT
TI Preparation of pyridinylarylureas and related compounds as inhibitors of p38 kinase.
IN Salituro, Francesco; Galullo, Vincent; Bellon, Steven; Bemis, Guy; Cochran, John
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9958502	A1	19991118	WO 1999-US10291	19990511
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9937923	A1	19991129	AU 1999-37923	19990511

PRAI US 1998-85053 19980511
US 1999-127626 19990401
US 1999-129099 19990413
WO 1999-US10291 19990511

GI



I



II

AB Title compds. e.g., [I; Q1, Q2 = substituted Ph, 5-6 membered heteroaryl, 8-10 membered bicyclyl; Y = N, C; Z = CH, N, COMe, CMe, CNH2, COH, CF; U = R, W; V = CONH2, PO(NH2)2, SO2NH2; W = NR2SO2N(R2)2, COR2, CO2R2, (substituted) alkyl, etc.; R = H, R2, N(R2)2, OR2, SR2, CO2R2, COR2, etc.; R2 = H, (substituted) alkyl, alkenyl], were prepd. Thus, o-tolylboronic acid, 2-bromo-3-dimethoxymethyl-6-(2,6-dichlorophenylamino)pyridine (prepn. given), Tl2CO3, and Pd(Ph3P)4 were refluxed in PhMe/EtOH followed

by aq. acid and base workup to give 2-(o-tolyl)-3-formyl-6-(2,6-dichlorophenylamino)pyridine, which was stirred with ClSO2NCO in CH2Cl2 followed by treatment of the product with NaBH4 in MeOH to give title compd. (II). Tested title compds. inhibited recombinant p38 kinase with IC50 = 0.02-0.56 .mu.M.

RE.CNT 4

RE

(1) Ciba Geigy AG; EP 0337943 A 1989
(2) Ciba Geigy AG; EP 0337944 A 1989
(3) Gallagher, T; WO 9733883 A 1997
(4) Galullo, V; WO 9827098 A 1998

L3 ANSWER 4 OF 23 MARPAT COPYRIGHT 2000 ACS
AN 129:81749 MARPAT
TI Preparation of annelated pyrimidinones and analogs as p38 kinase inhibitors
IN Bemis, Guy W.; Salituro, Francesco Gerald; Duffy, John Patrick; Cochran, John E.; Harrington, Edmund Martin; Murcko, Mark A.; et al.
PA Vertex Pharmaceuticals Inc., USA
SO PCT Int. Appl., 131 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9827098	A1	19980625	WO 1997-US23392	19971217
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5945418	A	19990831	US 1997-822373	19970320
	AU 9856105	A1	19980715	AU 1998-56105	19971217
	EP 951467	A1	19991027	EP 1997-952517	19971217
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	CN 1244867	A	20000216	CN 1997-181382	19971217
	NO 9902960	A	19990817	NO 1999-2960	19990617

PRAI US 1996-34288 19961218
US 1997-822373 19970320
US 1997-862925 19970610
WO 1997-US23392 19971217

GI



I



II

AB Title compds. [e.g., I; Q1 = (un)substituted (hetero)aryl; R1 = H, OH, alkyl, alkoxy; R5R6 = YR:YRC(XQ2):An or YR:YRCH:CQ2; A = N or (un)substituted CH; Q2 = (un)substituted (hetero)aryl; R = H, (un)substituted alkyl, amino(carbonyl), alkoxycarbonyl, etc.; RR = atoms to complete a ring; X = O, CO, CH2, NH, etc.; Y = N or C; n = 0 or 1] were prepd. Thus, PhCH2CN was arylated by 3,6-dichloropyridazine and the product thioetherified by PhSH to give PhCH(CN)ZSPh (Z =

pyridazine-3,6-diyl) which was hydrolized to the amide and the product cyclized to give title compd. II.

L3 ANSWER 5 OF 23 MARPAT COPYRIGHT 2000 ACS
AN 129:69033 MARPAT
TI Multicomponent system for altering, degrading, or bleaching lignin, lignin-containing materials, or similar substances, and method for its use
IN Freudenreich, Johannes; Stohrer, Juergen; Amann, Manfred; Mueller, Robert
PA Consortium fuer Elektrochemische Industrie G.m.b.H., Germany
SO Ger. Offen., 12 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19651099	A1	19980610	DE 1996-19651099	19961209
	WO 9826127	A1	19980618	WO 1997-EP6802	19971205
	W: AU, BR, CA, CN, JP, KR, NO, PL, RU, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9855603	A1	19980703	AU 1998-55603	19971205
	AU 719140	B2	20000504		
	EP 943032	A1	19990922	EP 1997-952038	19971205
	R: AT, DE, ES, SE, PT, FI				
	CN 1240008	A	19991229	CN 1997-180387	19971205
	JP 2000505844	T2	20000516	JP 1998-526185	19971205
PRAI	DE 1996-19651099	19961209			
	WO 1997-EP6802	19971205			

AB The title compns., esp. useful in cellulose pulp manuf., contain oxidants, mediators (hydroxylated heterocyclic amines bearing NO or SH groups or their derivs.), and optionally, oxidn. catalysts. Adding 20 mL H2O contg. 65.3 mg 8-hydroxy-5-nitrosoquinoline (acidified to pH 4.5) and 5 mL H2O contg. 15 units of laccase (from Trametes versicolor) to 5 g (dry basis) delignified softwood pulp, kneading for 2 min, and holding in O at 45.degree./1-10 bar for 1-4 h gave pulp with lignin degrdn. 11.6%.

not print art

L3 ANSWER 6 OF 23 MARPAT COPYRIGHT 2000 ACS
AN 128:13212 MARPAT
TI Bradykinin antagonist quinoline derivatives
IN Oku, Teruo; Kayakiri, Hiroshi; Satoh, Shigeki; Abe, Yoshito; Sawada, Yuki;
Inoue, Takayuki; Tanaka, Hirokazu
PA Fujisawa Pharmaceutical Co., Ltd., Japan; Oku, Teruo; Kayakiri, Hiroshi; Satoh, Shigeki; Abe, Yoshito; Sawada, Yuki; Inoue, Takayuki; Tanaka, Hirokazu
SO PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9741104	A1	19971106	WO 1997-JP1415	19970424
	W: AU, CA, CN, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9724054	A1	19971119	AU 1997-24054	19970424
	EP 900203	A1	19990310	EP 1997-919665	19970424
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 2000509066	T2	20000718	JP 1997-538734	19970424
	US 6083959	A	20000704	US 1998-147193	19981026
PRAI	AU 1996-9526	19960429			
	WO 1997-JP1415	19970424			

GI



I

AB Title compds. I (R1 = lower alkyl, R2 = a heterocyclic group, R3 = H, lower alkyl, halo, R4 = lower alkyl, halo, R5 = alkylamino, amido, X = lower alkylene) were prepd. by std. derivatizations of 8-hydroxyquinolines. The IC50 (M) was 3.3 X 10-9 for inhibition of bradykinin binding for 8-[2,6-dichloro-3-[N-methyl-N-[4-(dimethylcarbamoyl)cinnamoylglycyl]amino]benzyloxy]-2-methyl-4-(1-pyrazolyl)quinoline dihydrochloride.

L3 ANSWER 7 OF 23 MARPAT COPYRIGHT 2000 ACS
AN 127:161697 MARPAT
TI 2-Amino heterocycles and their therapeutic uses as leukotriene biosynthesis inhibitors
IN Es-Sayed, Mazen; Yamamoto, Masaru; Frobel, Klaus; Poll, Chris; Grix, Suzanna; Tudhope, Stephen
PA Bayer Aktiengesellschaft, Germany; Es-Sayed, Mazen; Yamamoto, Masaru; Frobel, Klaus; Poll, Chris; Grix, Suzanna; Tudhope, Stephen
SO PCT Int. Appl., 275 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9724328	A1	19970710	WO 1996-EP5643	19961216
	W: AU, BG, BR, BY, CA, CN, CZ, EE, HU, IL, IS, JP, KE, KP, KR, LT, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, UA, US, VN				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9713728	A1	19970728	AU 1997-13728	19961216

PRAI GB 1995-26560 19951227
WO 1996-EP5643 19961216
GI



II

AB 2-Amino heterocycles R1R2NCOR3 [I; R1 = H, Me, (un)substituted 6-membered arom. heterocycle contg. .ltoreq.2 N atoms and optionally benzo-fused; R2 = (un)substituted adamantyl, cycloalkyl, pyridyl, Ph, CH2Ph, tetralin-5-yl, 2-norbornyl, 1-azabicyclo[2.2.2]oct-3-yl; or NR1R2 forms .alpha.-carboline residue; R3 = (un)substituted or cyclic amino groups linked via a bond, carbonyl, or alkylene group] are disclosed. I can be used for the prodn. of medicaments which inhibit leukotriene synthesis (in particular LTB4), and are esp. useful for the treatment and control of respiratory diseases and inflammatory processes (no data). For instance, condensation of 2-chloropyridine with 4-MeOC6H4NH2 at 150.degree. gave 2-(4-methoxyanilino)pyridine, which reacted with ClCO2CCl3 and then HN(CH2Ph)2 in dioxane at 60.degree. to give title compd. II plus a byproduct.

L3 ANSWER 8 OF 23 MARPAT COPYRIGHT 2000 ACS
AN 126:157289 MARPAT
TI Benzamide derivatives and their use as vasopressin antagonists
IN Setoi, Hiroyuki; Ohkawa, Takehiko; Zenkoh, Tatsuya; Sawada, Hitoshi; Sato,
Kentaro; Tanaka, Hirokazu
PA Fujisawa Pharmaceutical Co., Ltd., Japan; Setoi, Hiroyuki; Ohkawa, Takehiko; Zenkoh, Tatsuya; Sawada, Hitoshi; Sato, Kentaro; Tanaka, Hirokazu
SO PCT Int. Appl., 322 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9641795	A1	19961227	WO 1996-JP1533	19960606
	W: AU, CA, CN, HU, IL, JP, KR, MX, NZ, SG, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2223869	AA	19961227	CA 1996-2223869	19960606
	AU 9659110	A1	19970109	AU 1996-59110	19960606
	EP 832061	A1	19980401	EP 1996-916324	19960606
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	CN 1192729	A	19980909	CN 1996-196175	19960606
	JP 11508244	T2	19990721	JP 1996-502896	19960606
	ZA 9604895	A	19961212	ZA 1996-4895	19960607
	US 6054457	A	20000425	US 1997-973103	19971209
PRAI	GB 1995-11694	19950609			
	WO 1996-JP1533	19960606			

GI



I



II

AB The invention relates to new benzamide derivs. having vasopressin antagonistic activity, and to pharmaceutically acceptable salts thereof, processes for their prepn., and pharmaceutical compns. The compds. are represented by formula I [R1 = (un)substituted aryl, cycloalkyl, heterocyclyl; R2 = H, (un)substituted alkyl, cycloalkyl; R3 = H, halo, OH, (un)substituted acyloxy, alkyl, (cyclo)alkoxy, NO2, amino, acyl; R4 = OH, halo, NO2, (un)substituted amino, acyloxy, alkoxy, alkylthio, alk(en/yn)yl, etc; R5 = H, alkyl, alkoxy, halo; A = bond, O, NH; E = alkylene, alkenylene, CO, SO2, etc.; X = CH:CH, CH:N, S; Y = CH, N]. Approx. 470 synthetic examples of I and over 100 intermediates are described. For instance, amidation of 2-(PhCH2O)C6H4CO2H with 4-H2NC6H4CONMeC6H4[O(CH2)5CO2Et]-2 (prepn. given), followed by sapon. of the ester, amidation with N-methylpiperazine, hydrogenolytic debenzylation, etherification with N-(3-bromopropyl)phthalimide, hydrazinolyis of the imide, and acidification, gave title compd. II as the di-HCl salt (III). In assays for binding at human vasopressin V1 receptors and cloned human V2 receptors in vitro, III had IC50 values of 14 and 1400 nM, resp.

L3 ANSWER 9 OF 23 MARPAT COPYRIGHT 2000 ACS
AN 126:48348 MARPAT
TI Colorants, printing ink compositions containing them and their use
IN Bradbury, Roy; Butters, Alan; Moscrop, Clive; Slark, Andrew
PA Zeneca Limited, UK; Bradbury, Roy; Butters, Alan; Moscrop, Clive; Slark, Andrew
SO PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9634916	A2	19961107	WO 1996-GB994	19960426
	WO 9634916	A3	19970103		
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 823927	A2	19980218	EP 1996-911052	19960426
	R: CH, DE, FR, GB, IT, LI				
	JP 11504958	T2	19990511	JP 1996-533099	19960426
	US 6099625	A	20000808	US 1998-945649	19980108
PRAI	GB 1995-8810	19950501			
	GB 1995-8874	19950502			
	WO 1996-GB994	19960426			

AB Ink compns. contain (XmZ)wX(Z1Xn)Q and their salts, wherein Q is a chromophore which absorbs electromagnetic radiation; X is an interactive functional group; Z and Z1 each independently is a spacer group; w and x each independently is 0 or an integer equal to or greater than 1; and m and n each independently is an integer equal to or greater than 1, provided that w and x are not both equal to zero and when one of w or x is 0 at least one of m and n is equal to or greater than 2. The compns. are suited for ink jet printing and electrophotog. In an example, N,N-bis(3-hydroxypropyl)aniline was obtained from PhNH2 and 3-chloro-1-propanol and coupled with diazotized 2-(4-aminophenyl)ethanol to give an azo dye.

L3 ANSWER 10 OF 23 MARPAT COPYRIGHT 2000 ACS
AN 125:275894 MARPAT
TI Preparation of heterocyclic compounds as ACAT inhibitors
IN Ishikawa, Kiyofumi; Hayama, Takashi; Kamei, Toshio; Nagata, Yasufumi
PA Banyu Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9626925	A1	19960906	WO 1996-JP412	19960223
W: JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI JP 1995-65263		19950301		
JP 1995-152173		19950526		

GI



I



II

AB The title compds. I [Ar represents Ph, naphthyl or pyridyl optionally having one to four substituents selected from the group consisting of lower alkyl, lower alkoxy and halogeno; R1 represents hydrogen or lower alkyl; R2 and R3 may be the same or different and each represents hydrogen, lower alkyl, lower alkoxy, lower alkylthio, mono(lower alkyl)amino or di(lower alkyl)amino, provided that the lower alkyl, lower alkoxy, lower alkylthio, mono(lower alkyl)amino or di(lower alkyl)amino may be substituted by pyrrolidino, etc. at arbitrary hydrogen atoms; n represents 0, 1 or 2; and X represents CH or N] are prepd. The title compd. II (prepn. given) at 0.3 .mu.M gave 100% inhibition of ACAT.

L3 ANSWER 11 OF 23 MARPAT COPYRIGHT 2000 ACS
AN 125:204523 MARPAT
TI Drugs for improvement of lipid metabolism
IN Shiraishi, Mitsuru; Watanabe, Toshifumi
PA Takeda Chemical Industries, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 111 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 08175994	A2	19960709	JP 1995-244938	19950922
PRAI	JP 1994-263512	19941027			

GI



I

AB Drugs of formula I (ring A is substituted benzene; ring B is substituted pyridine; Q = OH, OQ1, or Q1, where Q1 = substituted fatty hydrocarbon group; n = 0 or 1) and their pharmaceutically acceptable salts are prepd. for treatment of disorders of lipid metab. Thus, a capsules can be formulated which contain (Z)-2-(5-bromo-4-cyano-2-hydroxybenzoyl)-3-hydroxypyridine N-oxide O-tert-butyloxime (II) 1 mg, lactose 80 mg, microcryst. cellulose 60 mg, and magnesium stearate 9 mg. Given at 1 mg/kg dosage to rats with hypertriglyceridemia, II exhibited hypotriglyceridemic activity.

L3 ANSWER 12 OF 23 MARPAT COPYRIGHT 2000 ACS
AN 124:232488 MARPAT
TI Piperazine, piperidine, and tetrahydropyridine derivatives of indol-3-ylalkyl as 5-HT1D.alpha. agonists
IN Castro Pineiro, Jose Luis; Chambers, Mark Stuart; Hobbs, Sarah Christine; Matassa, Victor Giulio; Reeve, Austin John; Showell, Graham Andrew; Street, Leslie Joseph
PA Merck Sharp and Dohme Ltd., UK
SO PCT Int. Appl., 121 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9532196	A1	19951130	WO 1995-GB1129	19950518
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2190501	AA	19951130	CA 1995-2190501	19950518
	AU 9525296	A1	19951218	AU 1995-25296	19950518
	AU 694226	B2	19980716		
	EP 759918	A1	19970305	EP 1995-919502	19950518
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 10501212	T2	19980203	JP 1995-530123	19950518
	ZA 9508271	A	19960517	ZA 1995-8271	19951002
	US 5807857	A	19980915	US 1996-737769	19961115

PRAI	GB 1994-10080	19940519
	GB 1994-11954	19940615
	GB 1994-15805	19940804
	GB 1994-25448	19941216
	WO 1995-GB1129	19950518

GI



I



II

AB Title compds. I and their salts and prodrugs are disclosed [wherein Z = (un)substituted furan, thiophene, pyrrole, oxazole, thiazole, isoxazole, isothiazole, imidazole, pyrazole, oxadiazole, thiadiazole, triazole, or tetrazole; E = bond or C1-4 straight or branched alkylene; Q = C1-6 straight or branched alkylene, (un)substituted by OH; T = N or CH; U = N or CR2; V = O, S, or NR3; W-G = CH2N, CH2CH, or CH:C; R1 = (un)substituted C3-6 alkenyl or alkynyl, (hetero)arylalkyl; R2, R3 = H or C1-6 alkyl]. I show selective affinity for the 5-HT1D.alpha. receptor subtype, relative to the 5-HT1D.beta. subtype. I are useful for treatment and/or prevention of migraine and assocd. disorders, for which a subtype-selective agonist of 5-HT1D.alpha. receptors should elicit fewer side-effects, notably adverse cardiovascular events. Fifty-eight synthetic examples are given. For example, cyclocondensation of 4'-(1,2,4-triazol-4-yl)phenylhydrazine with 5-[4-(tert-butoxycarbonyl)piperazin-1-yl]pentanal di-Me acetal [prepns. given] in 4% H2SO4 gave 44% of a corresponding (indolylpropyl)piperazine deriv., which was N-alkylated with 4-(acetamido)benzaldehyde and NaBH3CN (50%) to give title compd. II. In 3 bioassays, all tested I showed at least 10-fold selectivity for 5-HT1D.alpha. over 5-HT1D.beta. receptors (no data for specific compds.).

L3 ANSWER 13 OF 23 MARPAT COPYRIGHT 2000 ACS
AN 124:175614 MARPAT
TI Process for the preparation of intermediates useful in the preparation of pyranyl cyanoguanidine derivatives
IN Godfrey, Jollie D., Jr.; Mueller, Richard H.; Sedergran, Thomas C.; Soundararajan, Nachimuthu
PA Squibb, E. R., and Sons, Inc., USA
SO U.S., 8 pp. Cont.-in-part of U.S. Ser. No. 975,498, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5463059	A	19951031	US 1993-128436	19931001
	EP 600617	A1	19940608	EP 1993-308845	19931105
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	FI 9304947	A	19940511	FI 1993-4947	19931109
	AU 9350543	A1	19940526	AU 1993-50543	19931109
	AU 660239	B2	19950615		
	HU 68501	A2	19950628	HU 1993-3185	19931109
	JP 06219985	A2	19940809	JP 1993-281067	19931110
	CN 1094712	A	19941109	CN 1993-114524	19931110
	US 5536833	A	19960716	US 1995-452238	19950526
PRAI	US 1992-975498	19921110			
	US 1993-128436	19931001			

GI



I



II

AB The title compds. [I; A, B, D are all C atoms or one is N or NO and the others are C atoms; R1, R2 = H, alkyl, arylalkyl; R3 = H, (un)substituted alkyl, CN, NO2, etc; R4 = H, alkyl, OH, alkoxy, (un)substituted NH2] [e.g., 4-[(1,1-dimethyl-2-propynyl)oxy]benzonitrile] are prepd. by alkylating a substituted phenol (II) (e.g., 4-cyanophenol) with an alkyne HC.tplbond.CC(X)R1R2 (X = Cl, Br, etc.) (e.g., 3-chloro-3-methyl-1-butyne)
in the presence of a catalytic amt. of a cuprous (e.g., CuCl) or cupric salt.

L3 ANSWER 14 OF 23 MARPAT COPYRIGHT 2000 ACS
AN 123:285792 MARPAT
TI Preparation of pyridylnaphthalene and pyridonylnaphthalene derivatives as antiasthmatics
IN Iwasaki, Tameo; Kondo, Kazuhiko; Ikezawa, Ichiro; Yoshikawa, Hideo; Yamagata, Shinsuke
PA Tanabe Seiyaku Co, Japan
SO Jpn. Kokai Tokkyo Koho, 45 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07101861	A2	19950418	JP 1994-183128	19940804

PRAI JP 1993-198308 19930810
GI



I

AB The title compds. I [R1, R2 = H, (un)substituted alkoxy, etc.; or R1R2 = alkylenedioxy; R3 = (un)substituted N-contg. 6-membered heterocyclic ring; OR4, OR5 = (protected) OH] are prepd. I [R1 = R2 = EtO; R4 = R5 = H; R3 = Q1] (II) (prepn. given) at 3 mg/Kg i. v. gave complete inhibition of histamine-induced bronchoconstriction in guinea pigs. II at 10 mg/Kg i. v. gave 63% inhibition of antigen-induced bronchoconstriction in guinea pigs. I [R1 = EtO; R2 = MeO; R3 = Q1; R4 = R5 = H] at 10 mg/Kg i. v. gave 80% inhibition of antigen-induced bronchoconstriction in guinea pigs.

L3 ANSWER 15 OF 23 MARPAT COPYRIGHT 2000 ACS
AN 123:198800 MARPAT
TI Preparation of [(azacyclomethyl)heterocyclyl]alkanoates and analogs as angiotensin II receptor antagonists
IN Carpino, Philip A.; Larson, Eric R.; Mylari, Banavara L.
PA USA
SO PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9502596	A1	19950126	WO 1994-IB187	19940701
	W: AU, BG, BR, BY, CA, CN, CZ, HU, JP, KR, KZ, LV, NO, NZ, PL, RO, RU, SK, UA, US, UZ				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9469794	A1	19950213	AU 1994-69794	19940701
	FI 9403359	A	19950116	FI 1994-3359	19940714
	BR 9500208	A	19970114	BR 1995-208	19950113
	US 5789415	A	19980804	US 1996-569133	19960111
PRAI	US 1993-92349	19930715			
	WO 1994-IB187	19940701			

GI



II

AB RCH2ZCR1R2R3 [I; R = azacyclyl group; R1,R2 = H, OH, alkyl, Ph, etc.; R1R2 = atoms to complete a (heterocyclic) ring; R3 = CHO, CO2H, CH2OH, tetrazolyl, etc.; Z = naphthylene, heterocyclylene, etc.] were prepd. Thus, Et 2-thienylacetate was cyclocondensed with cis-ClCH2CH:CHCH2Cl and the product formylated to give, in 2 addnl. steps, Et 1-(5-chloromethyl-2-thienyl)cyclopent-3-enecarboxylate which was condensed with 2-ethyl-5,7-dimethylimidazo[4,5-b]pyridine to give, after sapon., title compd. II. I had IC50 of .ltoreq.10-5M against SARILE AII binding at rat liver prepn. in vitro.

L3 ANSWER 16 OF 23 MARPAT COPYRIGHT 2000 ACS
AN 121:108774 MARPAT
TI Preparation of thiazole derivatives as insecticides and agrochemical and medical fungicides
IN Kumita, Izumi; Noda, Kaoru; Hashimoto, Sho; Matsuda, Michihiko; Iwasa, Takao
PA Nippon Soda Co., Ltd., Japan
SO PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9401423	A1	19940120	WO 1993-JP926	19930706
	W: CA, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	JP 06073032	A2	19940315	JP 1993-191584	19930706
PRAI	JP 1992-201787		19920707		

GI



I

II



III

AB The title compds. I [R1, R2, X = halo, alkyl, alkoxy, alkylthio; n = 0 - 3; R3 = H, amino-protecting group ; R4 = Ph, pyridyl or cycloalkyl, each of which may be substituted] are prepd. A mixt. of phenacyl bromide II and 1-(4-chlorophenyl)thiourea in EtOH was heated at 90.degree. for 2 h to give thiazole III. III in vitro showed MIC of 0.03 ppm against Trichophyton mentagrophytes spores. The title compds. also gave good control of Botrytis cinerea and have excellent insecticidal activities.

L3 ANSWER 17 OF 23 MARPAT COPYRIGHT 2000 ACS
(ALL HITs ARE ITERATION INCOMPLETES)
AN 120:245602 MARPAT
TI Preparation of 17-ethers and thioethers of 4-aza-steroids as steroid reductase inhibitors
IN Witzel, Bruce E.; Tolman, Richard L.; Rasmusson, Gary H.; Bakshi, Raman K.; Yang, Shu Shu
PA Merck and Co., Inc., USA
SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9323040	A1	19931125	WO 1993-US4746	19930519
	W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9342521	A1	19931213	AU 1993-42521	19930519
	AU 668180	B2	19960426		
	EP 641204	A1	19950308	EP 1993-911358	19930519
	EP 641204	B1	20000816		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 07508038	T2	19950907	JP 1993-503831	19930519
	US 5536727	A	19960716	US 1994-338572	19941117
PRAI	US 1992-886031	19920520			
	WO 1993-US4746	19930519			

GI



I

AB Title compds. [I; a, b both = single bonds, and R2 = H; or a = double bond, b = single bond, and R2 = H; or a = single bond, b = double bond, and R2 = null; R1 = H, aryl, (aryl)alkyl; R3 = H, Me, Et, OH, NH2, SMe; R4 = (substituted) alkyl, aryl, heterocyclyl; Z = XR4, (CHR1)nXR4; X = O, S, SO, SO2], were prepd. as inhibitors of steroid 5.alpha.-reductase enzymes 1 and 2 (no data). The compds. are useful for the treatment of hyperandrogenic disease conditions and diseases of the skin and scalp. Thus, 17-hydroxymethyl-4-methyl-5.alpha.-4-azaandrostan-3-one and diphenyldiazomethane in CH2Cl2 were treated dropwise with BF3.Et2O to give 17-diphenylmethoxymethyl-4-methyl-5.alpha.-4-azaandrostan-3-one.

L3 ANSWER 18 OF 23 MARPAT COPYRIGHT 2000 ACS
AN 120:19165 MARPAT
TI Use of heterocyclic nitrogen addenda to reduce continued coupling of magenta dye-forming couplers
IN Merkel, Paul Barrett; Singer, Stephen Paul
PA Eastman Kodak Co., USA
SO Eur. Pat. Appl., 23 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 545248	A1	19930609	EP 1992-120066	19921125
	EP 545248	B1	19950927		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	US 5441851	A	19950815	US 1991-797660	19911125
	JP 05241297	A2	19930921	JP 1992-313577	19921124
PRAI	US 1991-797660	19911125			

GI



AB The title material comprises a 2-equiv. pyrazolone magenta coupler and a heterocyclic N-compd. selected from protic imidazoles I and pyridine compds. II [R1, R2 = H, alkyl, alkenyl, alkoxy, aryl, III (one of R3 and R4 is alkylene and the other one is H, alkyl, alkenyl) with the proviso that .ltoreq.1 of R1 and R2 is III.

L3 ANSWER 19 OF 23 MARPAT COPYRIGHT 2000 ACS
AN 117:26560 MARPAT
TI Preparation of heterocyclo-fused imidazoles as angiotensin II antagonists
IN Ries, Uwe; Narr, Berthold; Bomhard, Andreas; Hauel, Norbert; Van Meel, Jacques; Wienen, Wolfgang; Entzeroth, Michael
PA Thomae, Dr. Karl, G.m.b.H., Germany
SO Eur. Pat. Appl., 68 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 470543	A1	19920212	EP 1991-113121	19910805
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	DE 4025358	A1	19920213	DE 1990-4025358	19900810
	DE 4031601	A1	19920423	DE 1990-4031601	19901005
	DE 4105827	A1	19920827	DE 1991-4105827	19910225
	CA 2048809	AA	19920211	CA 1991-2048809	19910808
	AU 9181717	A1	19920213	AU 1991-81717	19910809
	AU 650278	B2	19940616		
	HU 59140	A2	19920428	HU 1991-2665	19910809
	JP 06340665	A2	19941213	JP 1991-199654	19910809
PRAI	DE 1990-4025358	19900810			
	DE 1990-4031601	19901005			
	DE 1991-4105827	19910225			

GI



I

AB Title compds. I [1 or 2 of A1, A2, A3, A4 = N and the remainder = CH; R1 = H, Br, Cl, F, HO, alkyl, alkoxy, (substituted) (acyl)amino, (substituted) pyrrolidino, -piperidino, -hexamethyleneimino, -phthalimido, -2-oxoisoindolin-1-yl, -ureido; R2 = H, C1-3 alkyl; R3 = C1-6 alkyl; R4 = HO2C, NC, 1H-tetrazolyl, 1-trityltetrazolyl, C2-5 alkoxycarbonyl; R5 = H, Br, Cl, F, etc.], isomers, tautomers, enantiomers, and salts thereof, were prepd. tert-Bu 4'-[(2-n-butyl-5-methyl-6-phthalimido-3H-imidazo[4,5-b]pyridin-3-yl)methyl]biphenyl-2-carboxylate in CH2Cl2 was treated with F3CCO2H to give I (A1 = A2 = A3 = HC, A4 = N, R1 = 6-phthalimido, R2 = 5-Me, R3 = Bu, R4 = HO2C, R5 = H) (II). In rats, II and several addnl. I at 10, 20 and 30 mg/kg i.v. antagonized angiotensin II-induced increase in arterial blood presssure with pA2 values of 5.1-8.5. I showed no toxic effects at the above dosage levels. Pharmaceutical formulations

comprising I are given.

L3 ANSWER 20 OF 23 MARPAT COPYRIGHT 2000 ACS
(ALL HITs ARE ITERATION INCOMPLETES)
AN 116:13416 MARPAT
TI Pressure- and heat-sensitive recording materials with good sensitivity, storability and image stability
IN Sano, Masajiro; Takashima, Masanobu; Satomura, Masato
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03142277	A2	19910618	JP 1989-282319	19891030

AB The title materials utilizes coloration by contact between electron-donating leuco dye Ar1R1CH:CR2:CH:CHR3CR4R5Ar2 (Ar1, Ar2 = amine residue-contg. aryl or heterocyclic group; R1-4 = H, monovalent group; R5 = aryl group-contg. alkoxy group; R1-4 may bond together forming 4- to 12-membered rings with or without contg. heteroatom) and electron-accepting compd.

L3 ANSWER 21 OF 23 MARPAT COPYRIGHT 2000 ACS
AN 115:71405 MARPAT
TI Preparation of Me 7-[6-(dimethylamino)-4-(4-fluorophenyl)-2-isopropylpyridinyl]-3,5-dihydroxyheptenoates and analogs as HMG CoA reductase inhibitors
IN Fey, Peter; Angerbauer, Rolf; Huebsch, Walter; Philipps, Thomas; Bischoff, Hilmar; Petzinna, Dieter; Schmidt, Delf
PA Bayer A.-G., Fed. Rep. Ger.
SO Ger. Offen., 37 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 3929507	A1	19910307	DE 1989-3929507	19890906
US 5145857	A	19920908	US 1990-568442	19900815
EP 416383	A2	19910313	EP 1990-116202	19900824
EP 416383	A3	19911106		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 03093773	A2	19910418	JP 1990-230746	19900903
DD 299295	A5	19920409	DD 1990-343797	19900903
IL 95563	A1	19940624	IL 1990-95563	19900903
CA 2024576	AA	19910307	CA 1990-2024576	19900904
AU 9062170	A1	19910314	AU 1990-62170	19900904
AU 637632	B2	19930603		
ZA 9007054	A	19910731	ZA 1990-7054	19900905
HU 56546	A2	19910930	HU 1990-5809	19900906
PRAI DE 1989-3929507		19890906		

GI



I



Q



II

AB The title compds. [I; R = CHOHCH2CR4OHCH2CO2R7, hydroxylactone moiety Q; R1 = (un)substituted C6-10 aryl; R2 = CH2OR8, XR; R3, R4 = H, C1-8 alkyl, Ph, AR9; NR3R4 = 5- to 7-membered (un)satd. heterocyclyl group with .ltoreq.3 heteroatoms; R5 = C1-10 alkyl, C3-8 cycloalkyl; R6 = H, C1-10 alkyl; R7, R8 = (un)substituted C1-10 alkyl; R9 = amino, (un)substituted C1-8 alkyl, alkoxy, Ph; X = CH2CH2, CH:CH; A = CO, SO2] and their salts, HMG CoA reductase inhibitors useful as antihypercholesterolemics and for the treatment of hyperlipoproteinemia and atherosclerosis (no data), were prepd. The intermediate ketones were also claimed. A soln. of 6-dimethylamino-4-(4-fluorophenyl)-2-isopropylpyridine-3,5-dicarbaldehyde (multistep prepn. given) was coupled with di-Et [2-(cyclohexylamino)vinyl]phosphonate, the resulting 3,5-di(prop-2-en-1-al-yl) compd. condensed with MeCOCH2CO2Me, and the product reduced by Et3B/NaBH4 to give title compd. II.

L3 ANSWER 22 OF 23 MARPAT COPYRIGHT 2000 ACS
AN 114:101740 MARPAT
TI Preparation of fungicidal anilinocyanopyridines
IN Schubert, Juergen; Wild, Jochen; Harreus, Albrecht; Kuekenhoehner, Thomas;
Sauter, Hubert; Ammermann, Eberhard; Lorenz, Gisela
PA BASF A.-G., Fed. Rep. Ger.
SO Ger. Offen., 28 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3905238	A1	19900823	DE 1989-3905238	19890221
	CA 2008588	AA	19900821	CA 1990-2008588	19900125
	US 5081133	A	19920114	US 1990-470309	19900125
	IL 93171	A1	19930818	IL 1990-93171	19900125
	EP 384311	A1	19900829	EP 1990-103017	19900216
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE				
	AU 9049931	A1	19900830	AU 1990-49931	19900220
	AU 620211	B2	19920213		
	HU 53877	A2	19901228	HU 1990-865	19900220
	HU 203726	B	19910930		
	ZA 9001258	A	19911030	ZA 1990-1258	19900220
	JP 02255657	A2	19901016	JP 1990-38561	19900221

PRAI DE 1989-3905238 19890221
GI



I



II

AB Title compds. I [X = NO2, cyano, halo, alkylsulfonyl, (halo) C1-4 alkyl, C3-6 cycloalkyl, C1-4 alkoxy, (substituted) PhO or PhS; m = 1-3 and X groups are same or different when m > 1; R1 = H, halo, (halo)alkoxy, haloalkyl, (substituted) PhO or PhS; R2, R3 = H, halo, NO2, cyano, (halo)alkyl, alkylsulfonyl, SO2NR5R6 (R5, R6 = H, C1-4 alkyl), haloalkoxy,

CO2R5, CONR5R6; R4 = H, CO2R7 (R7 = halo(alkyl), PhCH2, (substituted) aryl), CONR5R6, CHO, COR7, SO2R7, C3-6 alkenyl or alkynyl], useful as fungicides, were prepd. For example, reaction of 2-amino-3,5-dicyano-6-ethoxy-4-isopropylpyridine with 3-chloro-2,6-dinitro-4-trifluoromethylchlorobenzene gave title compd. II in 58% yield. A foliar spray contg. II (0.05% by wt.) showed 95-100% control against Plasmopara viticola on grapes vs. 70% control by 2-(2,4-dinitro-6-trifluoromethylanilino)-5-trifluoromethylpyridine.

L3 ANSWER 23 OF 23 MARPAT COPYRIGHT 2000 ACS
AN 109:6320 MARPAT
TI Preparation of 2-[(pyridinioamino)alkyl]penemcarboxylates as antibacterial agents
IN Schneider, Peter
PA Ciba-Geigy A.-G., Switz.
SO Eur. Pat. Appl., 23 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 256990	A1	19880224	EP 1987-810462	19870814
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	FI 8703556	A	19880221	FI 1987-3556	19870817
	DK 8704321	A	19880221	DK 1987-4321	19870819
	NO 8703500	A	19880222	NO 1987-3500	19870819
	AU 8777217	A1	19880225	AU 1987-77217	19870819
	JP 63051387	A2	19880304	JP 1987-204285	19870819
	ZA 8706135	A	19880427	ZA 1987-6135	19870819
PRAI	CH 1986-3346		19860820		

GI



I Q Q1

AB The title compds. [I; R1 = CH2OH, MeCHOH; Z = 2- and 4-pyridinio group, Q or Q1; R2 = (un)substituted alkyl, alkenyl, Ph, pyridyl, etherified OH; R3, R4 = H, (un)substituted alkyl, NH2, (un)derivatized CO2H, etherified or esterified OH; m = 1-4] were prepd. (5R,6S)-2-Aminomethyl-6-[(1R)-1-hydroxyethyl]-2-penemcarboxylic acid and 4-chloro-2-hydroxymethyl-1-methylpyridinium iodide (prepn. given) were stirred 5 h in aq. soln. maintained at pH 7.5-7.9 to give I [R1 = (1R)-MeCHOH, Z = Q, R2 = Me, R3 = 2-(CH2OH), R4 = H] (II). Dry ampuls were prepd. each contg. 0.5 g II and 0.5 g mannitol. I are effective against, e.g., Staphylococcus aureus at <0.01 to .apprx.16 .mu.g/mL, Pseudomonas aeruginosa at 0.01 to .apprx.64 .mu.g/mL, and Bacteroides fragilis at 0.01 to .apprx.2 .mu.g/mL.

=>
Uploading 336266eg.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS
L1 STR



G1 [@1],[@2]

(If) and (Ih)

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 15:25:54 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1481 TO ITERATE

67.5% PROCESSED 1000 ITERATIONS 4 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 27313 TO 31927
PROJECTED ANSWERS: 4 TO 264

L2 4 SEA SSS SAM L1

=> s l1 sss ful

FULL SEARCH INITIATED 15:26:03 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 29616 TO ITERATE

100.0% PROCESSED 29616 ITERATIONS 55 ANSWERS
SEARCH TIME: 00.00.05

```
L3              55 SEA SSS FUL L1

=> s l3

L4              2 L3

=> d l4 1-2 bib,ab,hitstr
```

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2000 ACS
AN 1999:736658 CAPLUS
DN 131:336949
TI Preparation of pyridinylarylureas and related compounds as inhibitors of p38 kinase.
IN Salituro, Francesco; Galullo, Vincent; Bellon, Steven; Bemis, Guy; Cochran, John
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9958502	A1	19991118	WO 1999-US10291	19990511
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9937923	A1	19991129	AU 1999-37923	19990511

PRAI US 1998-85053 19980511
US 1999-127626 19990401
US 1999-129099 19990413
WO 1999-US10291 19990511
OS MARPAT 131:336949
AB Title compds. e.g., [I; Q1, Q2 = substituted Ph, 5-6 membered heteroaryl, 8-10 membered bicyclyl; Y = N, C; Z = CH, N, COMe, CMe, CNH2, COH, CF; U =
R, W; V = CONH2, PO(NH2)2, SO2NH2; W = NR2SO2N(R2)2, COR2, CO2R2, (substituted) alkyl, etc.; R = H, R2, N(R2)2, OR2, SR2, CO2R2, COR2, etc.;
R2 = H, (substituted) alkyl, alkenyl], were prepd. Thus, o-tolylboronic acid, 2-bromo-3-dimethoxymethyl-6-(2,6-dichlorophenylamino)pyridine (prepn. given), Tl2CO3, and Pd(Ph3P)4 were refluxed in PhMe/EtOH followed by aq. acid and base workup to give 2-(o-tolyl)-3-formyl-6-(2,6-dichlorophenylamino)pyridine, which was stirred with ClSO2NCO in CH2Cl2 followed by treatment of the product with NaBH4 in MeOH to give title compd. (II). Tested title compds. inhibited recombinant p38 kinase with IC50 = 0.02-0.56 .mu.M.
IT **250122-79-3P 250122-80-6P 250122-81-7P**
250122-91-9P 250122-92-0P 250122-93-1P
250122-94-2P 250122-95-3P 250122-96-4P
250122-97-5P 250122-98-6P 250122-99-7P
250123-00-3P 250123-01-4P 250123-02-5P
250123-03-6P 250123-04-7P 250123-05-8P
250123-06-9P 250123-07-0P 250123-08-1P
250123-09-2P 250123-10-5P 250123-11-6P
250123-12-7P 250123-13-8P 250123-14-9P
250123-15-0P 250123-16-1P 250123-17-2P
250123-18-3P 250123-19-4P 250123-20-7P

250123-21-8P 250123-22-9P 250123-23-0P
250123-24-1P 250123-25-2P 250123-26-3P
250123-27-4P 250123-28-5P 250123-30-9P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyridinylarylureas and related compds. as inhibitors of p38 kinase)

RN 250122-79-3 CAPLUS
CN Urea, N-(2,6-dichlorophenyl)-N-[5-(hydroxymethyl)-6-(2-methylphenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 250122-80-6 CAPLUS
CN Urea,
N-[5-[(acetyloxy)methyl]-6-(2,4-difluorophenyl)-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250122-81-7 CAPLUS
CN Urea, N-[5-[[(aminocarbonyl)oxy]methyl]-6-(2,4-difluorophenyl)-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250122-91-9 CAPLUS
CN Urea,
N-[5-[(aminocarbonyl)amino]-6-(4-fluoro-2-methylphenyl)-2-pyridinyl]-
N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250122-92-0 CAPLUS
CN Carbamic acid,
[6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-(4-fluoro-2-
methylphenyl)-3-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 250122-93-1 CAPLUS
CN Urea, N'-[6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-(4-fluoro-2-methylphenyl)-3-pyridinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 250122-94-2 CAPLUS
CN Urea,
N-[5-[(aminosulfonyl)amino]-6-(4-fluoro-2-methylphenyl)-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250122-95-3 CAPLUS
CN Urea, N-(2,6-difluorophenyl)-N-[5-[[(dimethylamino)sulfonyl]amino]-6-(4-fluoro-2-methylphenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 250122-96-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-(4-fluoro-2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 250122-97-5 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-(4-fluoro-2-methylphenyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 250122-98-6 CAPLUS
CN Urea, N-(2,6-difluorophenyl)-N-[6-(4-fluoro-2-methylphenyl)-5-(hydroxymethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 250122-99-7 CAPLUS
CN Urea, N-[5-(aminomethyl)-6-(4-fluoro-2-methylphenyl)-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-00-3 CAPLUS
CN Urea, N-(2,6-difluorophenyl)-N-[5-[(dimethylamino)methyl]-6-(4-fluoro-2-methylphenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 250123-01-4 CAPLUS
CN Urea,
N-(2,6-difluorophenyl)-N-[6-(4-fluoro-2-methylphenyl)-5-(1-hydroxy-1-methylethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 250123-02-5 CAPLUS
CN Urea, N-[5-(1-amino-1-methylethyl)-6-(4-fluoro-2-methylphenyl)-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-03-6 CAPLUS
CN Urea, N-(2,6-difluorophenyl)-N-[5-[1-(dimethylamino)-1-methylethyl]-6-(4-fluoro-2-methylphenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 250123-04-7 CAPLUS
CN Urea, N-(2,6-difluorophenyl)-N-[6-(4-fluoro-2-methylphenyl)-5-(2-hydroxyethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 250123-05-8 CAPLUS
CN Urea,
N-[5-(2-aminoethyl)-6-(4-fluoro-2-methylphenyl)-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-06-9 CAPLUS
CN Urea, N-(2,6-difluorophenyl)-N-[5-[2-(dimethylamino)ethyl]-6-(4-fluoro-2-methylphenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 250123-07-0 CAPLUS
CN 3-Pyridinepropanamide, 6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-(4-fluoro-2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 250123-08-1 CAPLUS
CN 3-Pyridinepropanoic acid, 6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-(4-fluoro-2-methylphenyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 250123-09-2 CAPLUS
CN 3-Pyridinepropanamide, 6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-(4-fluoro-2-methylphenyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 250123-10-5 CAPLUS
CN 3-Pyridineethanesulfonamide, 6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-(4-fluoro-2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 250123-11-6 CAPLUS
CN 3-Pyridineethanesulfonamide,
6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-
2-(4-fluoro-2-methylphenyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 250123-12-7 CAPLUS
CN Carbamic acid, [2-(1-piperazinyl)ethyl]-, [6-[(aminocarbonyl)(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)-3-pyridinyl]methyl ester (9CI) (CA INDEX NAME)



RN 250123-13-8 CAPLUS
CN Urea, N-(2,6-difluorophenyl)-N-[5-(2-hydroxyethyl)-6-(2-methylphenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 250123-14-9 CAPLUS
CN Urea,
N-(2,6-difluorophenyl)-N-[6-(2,4-difluorophenyl)-5-(2-hydroxyethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 250123-15-0 CAPLUS
CN Urea,
N-[4-(3-aminopropyl)-6-(3-chloro-2-methylphenyl)-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-16-1 CAPLUS
CN Urea,
N-[4-(3-aminopropyl)-6-(4-fluoro-2-methylphenyl)-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-17-2 CAPLUS
CN Urea, N-[4-(3-aminopropyl)-6-(2,4-difluorophenyl)-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-18-3 CAPLUS
CN Urea,
N-[6-(3-chloro-2-methylphenyl)-4-(1-piperazinylmethyl)-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-19-4 CAPLUS
CN Urea,
N-[6-(3-chloro-2-methylphenyl)-4-[(4-methyl-1-piperazinyl)methyl]-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-20-7 CAPLUS
CN Urea, N-[6-(3-chloro-2-methylphenyl)-4-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-21-8 CAPLUS

CN Urea, N-[6-(3-chloro-2-methylphenyl)-4-[[(3R,5S)-3,5-dimethyl-1-piperazinyl]methyl]-2-pyridinyl]-N-(2,6-difluorophenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 250123-22-9 CAPLUS
CN Urea, N-[6-(3-chloro-2-methylphenyl)-4-[[methyl[2-(2-pyridinyl)ethyl]amino]methyl]-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-23-0 CAPLUS
CN Urea, N-[6-(3-chloro-2-methylphenyl)-4-[(hexahydro-1H-1,4-diazepin-1-yl)methyl]-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-24-1 CAPLUS
CN Urea, N-[6-(3-chloro-2-methylphenyl)-4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-25-2 CAPLUS
CN Urea, N-[6-(3-chloro-2-methylphenyl)-4-[(hexahydro-1,5-diazocin-1(2H)-yl)methyl]-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-26-3 CAPLUS
CN Urea, N-[6-(3-chloro-2-methylphenyl)-4-[(hexahydro-5-methyl-1,5-diazocin-

1(2H)-yl)methyl]-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 250123-27-4 CAPLUS
CN Urea, N-(2,6-dichlorophenyl)-N-[6-(4-fluoro-2-methylphenyl)-5-(hydroxymethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 250123-28-5 CAPLUS
CN Urea, N-(2,6-difluorophenyl)-N-[6-(4-fluorophenyl)-5-(hydroxymethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 250123-30-9 CAPLUS
CN Urea, N-[5-amino-6-(4-fluoro-2-methylphenyl)-2-pyridinyl]-N-(2,6-difluorophenyl)- (9CI) (CA INDEX NAME)



IT **250122-90-8**
RL: RCT (Reactant)
(prepn. of pyridinylarylureas and related compds. as inhibitors of p38 kinase)
RN 250122-90-8 CAPLUS
CN Urea,
N-(2,6-difluorophenyl)-N-[6-(2,4-difluorophenyl)-5-(hydroxymethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



IT **250122-86-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of pyridinylarylureas and related compds. as inhibitors of p38 kinase)
RN 250122-86-2 CAPLUS
CN Urea, N-(2,6-dichlorophenyl)-N-[5-formyl-6-(2-methylphenyl)-2-pyridinyl]-(9CI) (CA INDEX NAME)



RE.CNT 4
RE
(1) Ciba Geigy AG; EP 0337943 A 1989
(2) Ciba Geigy AG; EP 0337944 A 1989
(3) Gallagher, T; WO 9733883 A 1997
(4) Galullo, V; WO 9827098 A 1998

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2000 ACS
AN 1998:424256 CAPLUS
DN 129:81749
TI Preparation of annelated pyrimidinones and analogs as p38 kinase inhibitors
IN Bemis, Guy W.; Salituro, Francesco Gerald; Duffy, John Patrick; Cochran, John E.; Harrington, Edmund Martin; Murcko, Mark A.; et al.
PA Vertex Pharmaceuticals Inc., USA
SO PCT Int. Appl., 131 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9827098	A1	19980625	WO 1997-US23392	19971217
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5945418	A	19990831	US 1997-822373	19970320
	AU 9856105	A1	19980715	AU 1998-56105	19971217
	EP 951467	A1	19991027	EP 1997-952517	19971217
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	CN 1244867	A	20000216	CN 1997-181382	19971217
	NO 9902960	A	19990817	NO 1999-2960	19990617

PRAI US 1996-34288 19961218
US 1997-822373 19970320
US 1997-862925 19970610
WO 1997-US23392 19971217
OS MARPAT 129:81749
AB Title compds. [e.g., I; Q1 = (un)substituted (hetero)aryl; R1 = H, OH, alkyl, alkoxy; R5R6 = YR:YRC(XQ2):An or YR:YRCH:CQ2; A = N or (un)substituted CH; Q2 = (un)substituted (hetero)aryl; R = H, (un)substituted alkyl, amino(carbonyl), alkoxycarbonyl, etc.; RR = atoms to complete a ring; X = O, CO, CH2, NH, etc.; Y = N or C; n = 0 or 1] were prepd. Thus, PhCH2CN was arylated by 3,6-dichloropyridazine and the product thioetherified by PhSH to give PhCH(CN)ZSPh (Z = pyridazine-3,6-diyl) which was hydrolized to the amide and the product cyclized to give title compd. II.
IT **209411-90-5P 209411-91-6P 209411-92-7P**
209411-93-8P 209411-94-9P 209411-95-0P
209411-96-1P 209411-97-2P 209411-98-3P
209411-99-4P 209412-00-0P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of annelated pyrimidinones and analogs as p38 kinase inhibitors)
RN 209411-90-5 CAPLUS

CN Urea, N-(2,6-dichlorophenyl)-N-(6-phenyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 209411-91-6 CAPLUS
CN Urea, N-(2,6-dichlorophenyl)-N-[6-(2-methylphenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 209411-92-7 CAPLUS
CN Urea, N-(2,6-dimethylphenyl)-N-[6-(4-fluorophenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 209411-93-8 CAPLUS

CN Urea, N-[6-(4-chlorophenyl)-2-pyridinyl]-N-(2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-94-9 CAPLUS
CN Urea, N-(2,6-difluorophenyl)-N-[6-(2-methylphenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 209411-95-0 CAPLUS
CN Urea, N-(2,6-difluorophenyl)-N-[6-(4-fluorophenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 209411-96-1 CAPLUS
CN Urea, N-(2,6-dimethylphenyl)-N-[6-(2-methylphenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 209411-97-2 CAPLUS
CN Urea, N-(2,6-dichlorophenyl)-N-[6-(4-methylphenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 209411-98-3 CAPLUS
CN Urea, N-(2,6-dichlorophenyl)-N-[6-(4-fluoro-2-methylphenyl)-2-pyridinyl]-(9CI) (CA INDEX NAME)



RN 209411-99-4 CAPLUS
CN Urea, N-(2,6-difluorophenyl)-N-[6-(4-fluoro-2-methylphenyl)-2-pyridinyl]-(9CI) (CA INDEX NAME)



RN 209412-00-0 CAPLUS
CN Urea, N-(6-chloro-1,3-benzodioxol-5-yl)-N-[6-(4-fluoro-2-methylphenyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


F
Me
O
C
NH2
N
N
O
O
Cl

```
=> d his

     (FILE 'HOME' ENTERED AT 15:25:19 ON 31 AUG 2000)

     FILE 'REGISTRY' ENTERED AT 15:25:23 ON 31 AUG 2000
L1                STRUCTURE UPLOADED
L2              4 S L1 SSS SAM
L3             55 S L1 SSS FUL

     FILE 'CAPLUS' ENTERED AT 15:26:17 ON 31 AUG 2000
L4              2 S L3

     FILE 'CAOLD' ENTERED AT 15:27:23 ON 31 AUG 2000

=> s l3

L5              0 L3
```

=>
Uploading 336266fh.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS
L1 STR



G1 [@1],[@2]

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 15:29:38 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 11866 TO ITERATE

8.4% PROCESSED 1000 ITERATIONS 1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 230814 TO 243826
PROJECTED ANSWERS: 31 TO 443

L2 1 SEA SSS SAM L1

=> s l1 sss ful

FULL SEARCH INITIATED 15:29:50 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 239798 TO ITERATE

100.0% PROCESSED 239798 ITERATIONS 95 ANSWERS
SEARCH TIME: 00.00.17

```
L3              95 SEA SSS FUL L1

=> s l3

L4              2 L3

=> d l4 1-2 bib,ab;hitstr
```

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2000 ACS
AN 1999:736658 CAPLUS
DN 131:336949
TI Preparation of pyridinylarylureas and related compounds as inhibitors of p38 kinase.
IN Salituro, Francesco; Galullo, Vincent; Bellon, Steven; Bemis, Guy; Cochran, John
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9958502	A1	19991118	WO 1999-US10291	19990511
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9937923	A1	19991129	AU 1999-37923	19990511

PRAI US 1998-85053 19980511
US 1999-127626 19990401
US 1999-129099 19990413
WO 1999-US10291 19990511
OS MARPAT 131:336949
AB Title compds. e.g., [I; Q1, Q2 = substituted Ph, 5-6 membered heteroaryl, 8-10 membered bicyclyl; Y = N, C; Z = CH, N, COMe, CMe, CNH2, COH, CF; U = R, W; V = CONH2, PO(NH2)2, SO2NH2; W = NR2SO2N(R2)2, COR2, CO2R2, (substituted) alkyl, etc.; R = H, R2, N(R2)2, OR2, SR2, CO2R2, COR2, etc.; R2 = H, (substituted) alkyl, alkenyl], were prepd. Thus, o-tolylboronic acid, 2-bromo-3-dimethoxymethyl-6-(2,6-dichlorophenylamino)pyridine (prepn. given), Tl2CO3, and Pd(Ph3P)4 were refluxed in PhMe/EtOH followed by aq. acid and base workup to give 2-(o-tolyl)-3-formyl-6-(2,6-dichlorophenylamino)pyridine, which was stirred with ClSO2NCO in CH2Cl2 followed by treatment of the product with NaBH4 in MeOH to give title compd. (II). Tested title compds. inhibited recombinant p38 kinase with IC50 = 0.02-0.56 .mu.M.
IT **250122-82-8P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyridinylarylureas and related compds. as inhibitors of p38 kinase)
RN 250122-82-8 CAPLUS
CN 2-Pyridineacetamide, 6-(3-chloro-2-methylphenyl)-.alpha.-(2,6-dichlorophenyl)-4-[(4-ethyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



IT **250123-29-6**
RL: RCT (Reactant)
(prepn. of pyridinylarylureas and related compds. as inhibitors of p38 kinase)
RN 250123-29-6 CAPLUS
CN 2-Pyridineacetamide, 6-(3-chloro-2-methylphenyl)-.alpha.-(2,6-dichlorophenyl)-4-[[(methylsulfonyl)oxy]methyl]- (9CI) (CA INDEX NAME)



RE.CNT 4
RE
(1) Ciba Geigy AG; EP 0337943 A 1989
(2) Ciba Geigy AG; EP 0337944 A 1989
(3) Gallagher, T; WO 9733883 A 1997
(4) Galullo, V; WO 9827098 A 1998

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2000 ACS
AN 1998:424256 CAPLUS
DN 129:81749
TI Preparation of annelated pyrimidinones and analogs as p38 kinase inhibitors
IN Bemis, Guy W.; Salituro, Francesco Gerald; Duffy, John Patrick; Cochran, John E.; Harrington, Edmund Martin; Murcko, Mark A.; et al.
PA Vertex Pharmaceuticals Inc., USA
SO PCT Int. Appl., 131 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9827098	A1	19980625	WO 1997-US23392	19971217
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5945418	A	19990831	US 1997-822373	19970320
	AU 9856105	A1	19980715	AU 1998-56105	19971217
	EP 951467	A1	19991027	EP 1997-952517	19971217
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	CN 1244867	A	20000216	CN 1997-181382	19971217
	NO 9902960	A	19990817	NO 1999-2960	19990617

PRAI US 1996-34288 19961218
US 1997-822373 19970320
US 1997-862925 19970610
WO 1997-US23392 19971217
OS MARPAT 129:81749
AB Title compds. [e.g., I; Q1 = (un)substituted (hetero)aryl; R1 = H, OH, alkyl, alkoxy; R5R6 = YR:YRC(XQ2):An or YR:YRCH:CQ2; A = N or (un)substituted CH; Q2 = (un)substituted (hetero)aryl; R = H, (un)substituted alkyl, amino(carbonyl), alkoxycarbonyl, etc.; RR = atoms to complete a ring; X = O, CO, CH2, NH, etc.; Y = N or C; n = 0 or 1] were
prepd. Thus, PhCH2CN was arylated by 3,6-dichloropyridazine and the product thioetherified by PhSH to give PhCH(CN)ZSPh (Z = pyridazine-3,6-diyl) which was hydrolized to the amide and the product cyclized to give title compd. II.
IT **209410-92-4P 209410-98-0P 209410-99-1P**
209411-00-7P 209411-01-8P 209411-02-9P
209411-03-0P 209411-04-1P 209411-05-2P
209411-06-3P 209411-07-4P 209411-08-5P
209411-09-6P 209411-10-9P 209411-11-0P
209411-12-1P 209411-13-2P 209411-14-3P
209411-15-4P 209411-16-5P 209411-17-6P
209411-18-7P 209411-19-8P 209411-20-1P
209411-21-2P 209411-22-3P 209411-23-4P
209411-24-5P 209411-25-6P 209411-26-7P

209411-27-8P 209411-28-9P 209411-29-0P
209411-30-3P 209411-31-4P 209411-32-5P
209411-33-6P 209411-34-7P 209411-35-8P
209411-36-9P 209411-37-0P 209411-38-1P
209411-39-2P 209411-40-5P 209411-41-6P
209411-42-7P 209411-43-8P 209411-44-9P
209411-45-0P 209411-46-1P 209411-47-2P
209411-48-3P 209411-49-4P 209411-50-7P
209411-51-8P 209411-52-9P 209411-53-0P
209411-54-1P 209411-55-2P 209411-56-3P
209411-57-4P 209411-58-5P 209411-59-6P
209411-60-9P 209411-61-0P 209411-62-1P
209411-63-2P 209411-64-3P 209411-65-4P
209411-66-5P 209411-67-6P 209411-68-7P
209411-69-8P 209411-70-1P 209411-71-2P
209411-72-3P 209411-74-5P 209411-75-6P
209411-76-7P 209411-77-8P 209411-78-9P
209411-79-0P 209411-80-3P 209411-81-4P
209411-82-5P 209411-83-6P 209411-84-7P
209411-85-8P 209411-86-9P 209411-87-0P
209411-88-1P 209411-89-2P 209412-01-1P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of annelated pyrimidinones and analogs as p38 kinase inhibitors)

RN 209410-92-4 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-5-(phenylthio)- (9CI) (CA INDEX NAME)



RN 209410-98-0 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-5-(hydroxyphenylmethyl)- (9CI) (CA INDEX NAME)



RN 209410-99-1 CAPLUS
CN 2-Pyridineacetamide, 5-benzoyl-.alpha.-(2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-00-7 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[2-(hydroxymethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-01-8 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[2-[(methylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 209411-02-9 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[2-(1-piperazinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-03-0 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 209411-04-1 CAPLUS
CN 2-Pyridineacetamide, 6-(4-chlorophenyl)-.alpha.-(2,6-dichlorophenyl)-
(9CI) (CA INDEX NAME)



RN 209411-05-2 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(4-methylphenyl)-
(9CI) (CA INDEX NAME)



RN 209411-06-3 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(3-methylphenyl)-
(9CI) (CA INDEX NAME)



RN 209411-07-4 CAPLUS
CN 2-Pyridineacetamide, 6-(3-chloro-4-fluorophenyl)-.alpha.-(2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-08-5 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-09-6 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2-chloro-6-fluorophenyl)-6-phenyl- (9CI) (CA INDEX NAME)



RN 209411-10-9 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[2-[(hydroxyimino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 209411-11-0 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(3-nitrophenyl)- (9CI)
(CA INDEX NAME)



RN 209411-12-1 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-13-2 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-14-3 CAPLUS
CN 2-Pyridineacetamide, 6-(3-chlorophenyl)-.alpha.-(2,6-dichlorophenyl)-(9CI) (CA INDEX NAME)



RN 209411-15-4 CAPLUS
CN Benzoic acid, 4-[6-[2-amino-1-(2,6-dichlorophenyl)-2-oxoethyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 209411-16-5 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(4-formylphenyl)- (9CI) (CA INDEX NAME)



RN 209411-17-6 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 209411-18-7 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 209411-19-8 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2-chloro-6-fluorophenyl)-6-(3-nitrophenyl)-
(9CI) (CA INDEX NAME)



RN 209411-20-1 CAPLUS
CN 2-Pyridineacetamide,
.alpha.-(2-chloro-6-fluorophenyl)-6-(4-fluorophenyl)-
(9CI) (CA INDEX NAME)



RN 209411-21-2 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(3-formylphenyl)-
(9CI) (CA INDEX NAME)



RN 209411-22-3 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(3-methoxyphenyl)-
(9CI) (CA INDEX NAME)



RN 209411-23-4 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(3-fluorophenyl)-
(9CI) (CA INDEX NAME)



RN 209411-24-5 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(2-methoxyphenyl)-
(9CI) (CA INDEX NAME)



RN 209411-25-6 CAPLUS
CN 2-Pyridineacetamide, 6-(2,4-dichlorophenyl)-.alpha.-(2,6-dichlorophenyl)-
(9CI) (CA INDEX NAME)



RN 209411-26-7 CAPLUS
CN 2-Pyridineacetamide, 6-(5-chloro-2-thienyl)-.alpha.-(2,6-dichlorophenyl)-
(9CI) (CA INDEX NAME)



RN 209411-27-8 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(2-formylphenyl)-
(9CI) (CA INDEX NAME)



RN 209411-28-9 CAPLUS
CN 2-Pyridineacetamide,
.alpha.-(2-chloro-6-fluorophenyl)-6-(4-chlorophenyl)-
(9CI) (CA INDEX NAME)



RN 209411-29-0 CAPLUS
CN 2-Pyridineacetamide,
.alpha.-(2-chloro-6-fluorophenyl)-6-(4-methylphenyl)-
(9CI) (CA INDEX NAME)



RN 209411-30-3 CAPLUS
CN 2-Pyridineacetamide,
.alpha.-(2-chloro-6-fluorophenyl)-6-(3-methylphenyl)-
(9CI) (CA INDEX NAME)



RN 209411-31-4 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2-chloro-6-fluorophenyl)-6-(3-chloro-4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-32-5 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2-chloro-6-fluorophenyl)-6-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-33-6 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2-chloro-6-fluorophenyl)-6-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 209411-34-7 CAPLUS
CN Benzoic acid, 4-[6-[2-amino-1-(2-chloro-6-fluorophenyl)-2-oxoethyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 209411-35-8 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2-chloro-6-fluorophenyl)-6-(4-formylphenyl)- (9CI) (CA INDEX NAME)



RN 209411-36-9 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2-chloro-6-fluorophenyl)-6-(2-thienyl)-(9CI) (CA INDEX NAME)



RN 209411-37-0 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2-chloro-6-fluorophenyl)-6-(3-thienyl)-(9CI) (CA INDEX NAME)



RN 209411-38-1 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2-chloro-6-fluorophenyl)-6-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-39-2 CAPLUS
CN 2-Pyridineacetamide,
.alpha.-(2-chloro-6-fluorophenyl)-6-(3-chlorophenyl)-
(9CI) (CA INDEX NAME)



RN 209411-40-5 CAPLUS
CN 2-Pyridineacetamide,
.alpha.-(2-chloro-6-fluorophenyl)-6-(3-formylphenyl)-
(9CI) (CA INDEX NAME)



RN 209411-41-6 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2-chloro-6-fluorophenyl)-6-(2,4-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-42-7 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2-chloro-6-fluorophenyl)-6-(5-chloro-2-thienyl)- (9CI) (CA INDEX NAME)



RN 209411-43-8 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2-chloro-6-fluorophenyl)-6-(2-formylphenyl)-

(9CI) (CA INDEX NAME)



RN 209411-44-9 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,5-dichlorophenyl)-6-phenyl- (9CI) (CA INDEX NAME)



RN 209411-45-0 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[2-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-46-1 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[2-[[(2-hydroxyethyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 209411-47-2 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2-chloro-6-fluorophenyl)-6-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 209411-48-3 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2-chloro-6-fluorophenyl)-6-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-49-4 CAPLUS
CN 2-Pyridineacetamide,
.alpha.-(2-chloro-6-fluorophenyl)-6-(2-methoxyphenyl)-
(9CI) (CA INDEX NAME)



RN 209411-50-7 CAPLUS
CN 2-Pyridineacetamide, 6-(2-benzofuranyl)-.alpha.-(2,6-dichlorophenyl)-
(9CI) (CA INDEX NAME)



RN 209411-51-8 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(4-methoxyphenyl)-
(9CI) (CA INDEX NAME)



RN 209411-52-9 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2-chloro-6-fluorophenyl)-6-[3-
(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-53-0 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(2-naphthalenyl)-
(9CI) (CA INDEX NAME)



RN 209411-54-1 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(4-amino-2,6-dichlorophenyl)-6-(4-fluoro-2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 209411-55-2 CAPLUS
CN 2-Pyridineacetamide, 6-benzo[b]thien-2-yl-.alpha.-(2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-56-3 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2-chloro-6-fluorophenyl)-6-(3-formyl-2-furanyl)- (9CI) (CA INDEX NAME)



RN 209411-57-4 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[2-[(phenylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 209411-58-5 CAPLUS
CN 2-Pyridineacetamide, 6-[2-[[(2-aminoethyl)amino]methyl]phenyl]-.alpha.-(2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-59-6 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[2-[[(2,3-dihydroxypropyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 209411-60-9 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(4-fluoro-1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 209411-61-0 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-difluorophenyl)-6-phenyl- (9CI) (CA INDEX NAME)



RN 209411-62-1 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2-chloro-6-fluorophenyl)-6-(4-fluoro-2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 209411-63-2 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 209411-64-3 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(4-fluoro-2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 209411-65-4 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-66-5 CAPLUS
CN 2-Pyridineacetamide, 6-(2,3-dichlorophenyl)-.alpha.-(2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-67-6 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(2-fluorophenyl)-
(9CI) (CA INDEX NAME)



RN 209411-68-7 CAPLUS
CN 2-Pyridineacetamide, 6-(2-chlorophenyl)-.alpha.-(2,6-dichlorophenyl)-
(9CI) (CA INDEX NAME)



RN 209411-69-8 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(2,3-dimethylphenyl)-
(9CI) (CA INDEX NAME)



RN 209411-70-1 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(2-ethylphenyl)-
(9CI)
(CA INDEX NAME)



RN 209411-71-2 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[2-(2-
hydroxyethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-72-3 CAPLUS

CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-74-5 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[2-(methoxymethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-75-6 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(2-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 209411-76-7 CAPLUS
CN 2-Pyridineacetamide, 6-[3,5-bis(trifluoromethyl)phenyl]-.alpha.-(2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-77-8 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(3,4,5-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-78-9 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[3-(hydroxymethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-79-0 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dimethylphenyl)-6-phenyl- (9CI) (CA INDEX NAME)



RN 209411-80-3 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[4-fluoro-2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-81-4 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(3,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-82-5 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[4-fluoro-2-[(methoxymethoxy)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 209411-83-6 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[4-fluoro-2-(methoxymethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-84-7 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(4-fluoro-2-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 209411-85-8 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(2,4-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 209411-86-9 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(6-chloro-1,3-benzodioxol-5-yl)-6-phenyl- (9CI) (CA INDEX NAME)



RN 209411-87-0 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-[4-fluoro-2-(hydroxymethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 209411-88-1 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(4-fluoro-3-methylphenyl)- (9CI) (CA INDEX NAME)



RN 209411-89-2 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-(2,4,6-trifluorophenyl)- (9CI) (CA INDEX NAME)



RN 209412-01-1 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-6-phenyl- (9CI) (CA INDEX NAME)



```
=> log y
```

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	136.71	136.86

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-12.19	-12.19

```
STN INTERNATIONAL LOGOFF AT 13:40:00 ON 31 AUG 2000
```

=>
Uploading 336266.str

L4 STRUCTURE UPLOADED

=> d l4

L4 HAS NO ANSWERS
L4 STR





G1 N,CH
G2 [@1],[@2]

Structure attributes must be viewed using STN Express query preparation.

=> s l4 sss sam

SAMPLE SEARCH INITIATED 11:33:40 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 683 TO ITERATE

100.0% PROCESSED 683 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 12093 TO 15227
PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L4

=> s l4 sss ful

FULL SEARCH INITIATED 11:33:57 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 12951 TO ITERATE

100.0% PROCESSED 12951 ITERATIONS 3 ANSWERS

SEARCH TIME: 00.00.02

L6 3 SEA SSS FUL L4

=> d scan l6

L6 3 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN 2-Pyridineacetamide, 5-benzoyl-.alpha.-(2,6-dichlorophenyl)- (9CI)
MF C20 H14 Cl2 N2 O2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 3 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-5-(phenylthio)- (9CI)
MF C19 H14 Cl2 N2 O S



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 3 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN 2-Pyridineacetamide,
.alpha.-(2,6-dichlorophenyl)-5-(hydroxyphenylmethyl)-
(9CI)
MF C20 H16 Cl2 N2 O2



ALL ANSWERS HAVE BEEN SCANNED

```
=> file caplus

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   126.90     127.95

FILE 'CAPLUS' ENTERED AT 11:34:39 ON 31 AUG 2000
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1967 - 31 Aug 2000  VOL 133 ISS 9
FILE LAST UPDATED: 30 Aug 2000  (20000830/ED)
```

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

Now you can extend your author, patent assignee, patent information, and title searches back to 1907. The records from 1907-1966 now have this searchable data in CAOLD. You now have electronic access to all of CA: 1907 to 1966 in CAOLD and 1967 to the present in CAPLUS on STN.

```
=> d his

     (FILE 'HOME' ENTERED AT 11:24:05 ON 31 AUG 2000)

     FILE 'REGISTRY' ENTERED AT 11:24:10 ON 31 AUG 2000
L1                STRUCTURE UPLOADED
L2                STRUCTURE UPLOADED
L3             20 S L2 SSS SAM

     FILE 'STNGUIDE' ENTERED AT 11:25:46 ON 31 AUG 2000

     FILE 'REGISTRY' ENTERED AT 11:33:02 ON 31 AUG 2000
L4                STRUCTURE UPLOADED
L5              0 S L4 SSS SAM
L6              3 S L4 SSS FUL

     FILE 'CAPLUS' ENTERED AT 11:34:39 ON 31 AUG 2000

=> s l6

L7              1 L6

=> d l7 bib,ab,hitstr
```

L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2000 ACS
AN 1998:424256 CAPLUS
DN 129:81749
TI Preparation of annelated pyrimidinones and analogs as p38 kinase inhibitors
IN Bemis, Guy W.; Salituro, Francesco Gerald; Duffy, John Patrick; Cochran, John E.; Harrington, Edmund Martin; Murcko, Mark A.; et al.
PA Vertex Pharmaceuticals Inc., USA
SO PCT Int. Appl., 131 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9827098	A1	19980625	WO 1997-US23392	19971217
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5945418	A	19990831	US 1997-822373	19970320
AU 9856105	A1	19980715	AU 1998-56105	19971217
EP 951467	A1	19991027	EP 1997-952517	19971217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1244867	A	20000216	CN 1997-181382	19971217
NO 9902960	A	19990817	NO 1999-2960	19990617

PRAI US 1996-34288 19961218
US 1997-822373 19970320
US 1997-862925 19970610
WO 1997-US23392 19971217
OS MARPAT 129:81749
AB Title compds. [e.g., I; Q1 = (un)substituted (hetero)aryl; R1 = H, OH, alkyl, alkoxy; R5R6 = YR:YRC(XQ2):An or YR:YRCH:CQ2; A = N or (un)substituted CH; Q2 = (un)substituted (hetero)aryl; R = H, (un)substituted alkyl, amino(carbonyl), alkoxycarbonyl, etc.; RR = atoms to complete a ring; X = O, CO, CH2, NH, etc.; Y = N or C; n = 0 or 1] were prepd. Thus, PhCH2CN was arylated by 3,6-dichloropyridazine and the product thioetherified by PhSH to give PhCH(CN)ZSPh (Z = pyridazine-3,6-diyl) which was hydrolized to the amide and the product cyclized to give title compd. II.
IT **209410-92-4P 209410-98-0P 209410-99-1P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of annelated pyrimidinones and analogs as p38 kinase inhibitors)
RN 209410-92-4 CAPLUS
CN 2-Pyridineacetamide, .alpha.-(2,6-dichlorophenyl)-5-(phenylthio)- (9CI) (CA INDEX NAME)



RN 209410-98-0 CAPLUS
CN 2-Pyridineacetamide,
.alpha.-(2,6-dichlorophenyl)-5-(hydroxyphenylmethyl)-
(9CI) (CA INDEX NAME)



RN 209410-99-1 CAPLUS
CN 2-Pyridineacetamide, 5-benzoyl-.alpha.-(2,6-dichlorophenyl)- (9CI) (CA INDEX NAME)



```
=> file caold

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     4.27     132.22

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -0.56      -0.56

FILE 'CAOLD' ENTERED AT 11:35:11 ON 31 AUG 2000
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED:  01 May 1997 (19970501/UP)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.  Title keywords, authors, patent
  assignees, and patent information, e.g., patent numbers, are
  now searchable from 1907-1966.  TIFF images of CA abstracts
  printed between 1907-1966 are available in the PAGE
  display formats.

  This file supports REGistRY for direct browsing and searching of
  all substance data from the REGISTRY file.  Enter HELP FIRST for
  more information.

=> d his


     (FILE 'HOME' ENTERED AT 11:24:05 ON 31 AUG 2000)

     FILE 'REGISTRY' ENTERED AT 11:24:10 ON 31 AUG 2000
L1                STRUCTURE UPLOADED
L2                STRUCTURE UPLOADED
L3             20 S L2 SSS SAM

     FILE 'STNGUIDE' ENTERED AT 11:25:46 ON 31 AUG 2000

     FILE 'REGISTRY' ENTERED AT 11:33:02 ON 31 AUG 2000
L4                STRUCTURE UPLOADED
L5              0 S L4 SSS SAM
L6              3 S L4 SSS FUL

     FILE 'CAPLUS' ENTERED AT 11:34:39 ON 31 AUG 2000
L7              1 S L6

     FILE 'CAOLD' ENTERED AT 11:35:11 ON 31 AUG 2000

=> s l6

L8              0 L6
```